

ASX ANNOUNCEMENT

R&D TAX CREDIT RECEIVED

Sydney, 6 June 2014: Benitec Biopharma Limited (ASX: BLT) today received a \$775,833 cash refund under the Federal Government's R&D Tax Incentive Scheme. The refund relates to the costs of research and development conducted by the company which qualify for the Federal Government's R&D Tax Incentive Scheme's 45% refund on eligible R&D expenditure.

The funds will be used to advance Benitec's human therapeutic programs in gene silencing.

For further information, please contact the persons below, or visit the Benitec website at www.benitec.com.

<i>Company</i>	<i>Investor relations</i>
A Carl Stubbings b Chief Business Officer o Tel: +61 (2) 9555 6986 u Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) (OTC Code: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.